VTVT · vTv Therapeutics Inc.

vTv Therapeutics delivered a transformative Q1 2026 with net income of $24.1 million, reversing a $5.1 million loss from Q1 2025, primarily fueled by $36.8 million in revenue—likely tied to the $20 million upfront payment from the February 2026 Newsoara Biopharma license amendment for HPP737. This non-dilutive capital infusion boosted cash to $98.1 million from $88.9 million at year-end 2025, after offsetting R&D spend, positioning the company to fund operations through the pivotal Phase 3 CATT1 topline data readout. R&D expenses surged 218% to $9.0 million, reflecting intensified investment in the CATT1 trial for cadisegliatin, an oral adjunctive therapy for type 1 diabetes with FDA Breakthrough Therapy designation. Enrollment progresses steadily toward Q3 2026 completion, bolstered by expanded sites and strong investigator/patient engagement, as highlighted by CEO Paul Sekhri. G&A rose modestly to $4.6 million amid corporate support for clinical advancement. The strengthened balance sheet underscores disciplined execution, enabling focus on cadisegliatin as a potential first-in-class glucokinase activator to improve glycemic control via hepatic glucose uptake.